Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery
Sponsor : Nona Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
Nona Biosciences Announces Collaboration with Evive Biotech to Accelerate Antibody Discovery
Details : The collaboration aims to accelerate the process of antibody discovery and drug development based on the Harbour Mice® antibody technology platform of Nona Biosciences.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 10, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery
Sponsor : Nona Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Benegrastim
Therapeutic Area : Hematology
Study Phase : Phase III
Recipient : Aurobindo Pharma Limited
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Aurobindo Unit, Evive Biotech Ink Licensing Pact to Commercialise CIN Treatment Product in US
Details : Under the terms of the agreement, Evive will be responsible for the ongoing development, manufacturing, registration, and supply of Ryzneuta (benegrastim), while Acrotech will use its sales and commercialisation capabilities to market and distribute the ...
Product Name : Ryzneuta
Product Type : Protein
Upfront Cash : Undisclosed
November 23, 2022
Lead Product(s) : Benegrastim
Therapeutic Area : Hematology
Highest Development Status : Phase III
Recipient : Aurobindo Pharma Limited
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : F-652
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of F-652 in Subjects With Corona Virus Disease 2019 (COVID-19) Pneumonia
Details : F-652 is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
January 25, 2022
Lead Product(s) : F-652
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : F-652
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19
Details : F-652 is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
August 04, 2020
Lead Product(s) : F-652
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Efbemalenograstim Alpha
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Evive Biotech meets Promising Results at Global Ph III Trial for Neutropenia Treatment
Details : Safety and efficacy endpoints met successfully in pivotal trial for F-627 (efbemalenograstim alfa), a novel long-acting G-CSF . F-627 has proven that it is at least as efficacious and safe as NEULASTA®, which is the current standard of care.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
July 08, 2020
Lead Product(s) : Efbemalenograstim Alpha
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Compare the Efficacy and Safety of F-627 and GRAN®
Details : F-627 is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
November 22, 2019
Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma
Details : Recombinant Anti-CD19/CD3 Bispecific Antibody is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, B-Cell.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 14, 2019
Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Details : F-627 is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
August 17, 2017
Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Details : F-627 is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
August 19, 2016
Lead Product(s) : F-627
Therapeutic Area : Hematology
Study Phase : Phase I
Sponsor : Fudan University
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Details : F-627 is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neutropenia.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
August 19, 2015
Lead Product(s) : F-627
Therapeutic Area : Hematology
Highest Development Status : Phase I
Sponsor : Fudan University
Deal Size : Inapplicable
Deal Type : Inapplicable